000			03347nam a22005537a 4500
008			190621s20192019 xxu||||| |||| 00| 0 eng d
022			_a1346-9843
040			_aOvid MEDLINE(R)
099			_a31118354
245			_aEffect of Statin Therapy on Fibrous Cap Thickness in Coronary Plaque on Optical Coherence Tomography - Review and Meta-Analysis.
251			_aCirculation Journal. 83(7):1480-1488, 2019 06 25.
252			_aCirc J. 83(7):1480-1488, 2019 06 25.
252			_zCirc J. 2019 May 22
253			_aCirculation journal : official journal of the Japanese Circulation Society
260			_c2019
260			_fFY2019
265			_saheadofprint
265			_sppublish
266			_d2019-06-21
268			_aCirculation Journal. 2019 May 22
520			_aBACKGROUND: Statin therapy has been shown to result in coronary plaque regression, but the relationship between statin use and stabilization of coronary plaque has not been elucidated. We conducted a systematic review and meta-analysis to evaluate the effect of statin therapy on fibrous cap thickness (FCT) on optical coherence tomography (OCT).Methods and Results:Nine OCT studies (6 randomized controlled trials and 3 observational studies) were enrolled with a total of 341 patients (390 lesions). Arms of the studies were grouped according to statin type and/or dose. Random effects meta-analysis was used to estimate a pooled mean change in FCT from baseline to follow-up. The overall effect mean FCT change was 67.7 micro m (95% CI: 51.4-84.1, I<sup>2</sup>=95.0%, P<0.001). All statin groups had an increase in FCT, but the magnitude of the increase differed according to the statin. Two homogeneous subgroups with I<sup>2</sup>=0 were identified: mean FCT change was 27.8 micro m (for subgroup atorvastatin 5 mg and rosuvastatin), and 61.9 micro m (for subgroup atorvastatin 20 mg, fluvastatin 30 mg, and pitavastatin 4 mg). On meta-regression modeling, statin therapy alone explained most of the change in FCT.
520			_aCONCLUSIONS: Statin therapy induced a significant increase in FCT as assessed on OCT, independent of coronary risk factors and other medications.
546			_aEnglish
650			_a*Coronary Artery Disease
650			_a*Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
650			_a*Plaque, Atherosclerotic
650			_a*Tomography, Optical Coherence
650			_aCoronary Artery Disease/dg [Diagnostic Imaging]
650			_aCoronary Artery Disease/dt [Drug Therapy]
650			_aFemale
650			_aHumans
650			_aMale
650			_aObservational Studies as Topic
650			_aPlaque, Atherosclerotic/dg [Diagnostic Imaging]
650			_aPlaque, Atherosclerotic/dt [Drug Therapy]
650			_aRandomized Controlled Trials as Topic
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aBeyene, Solomon
700			_aGarcia-Garcia, Hector M
700			_aHideo-Kajita, Alexandre
700			_aKolm, Paul
700			_aKuku, Kayode
700			_aOzaki, Yuichi
700			_aWaksman, Ron
790			_aBeyene SS, Garcia-Garcia HM, Hideo-Kajita A, Kolm P, Kuku KO, Ozaki Y, Waksman R
856			_uhttps://dx.doi.org/10.1253/circj.CJ-18-1376 _zhttps://dx.doi.org/10.1253/circj.CJ-18-1376
942			_cART _dArticle
999			_c4323 _d4323